Navigation Links
Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC
Date:4/10/2008

rmaceutical industry: monoclonal antibodies and recombinant protein products. Laureate Pharma, Inc. is a wholly owned subsidiary of Safeguard Scientifics, Inc. (NYSE: SFE) (http://www.safeguard.com). For more information, contact Michael Cavanaugh, Vice President Sales, Marketing, and Business Development at (609) 919-3400, or info@laureatepharma.com or visit http://www.laureatepharma.com .

About Alopexx Pharmaceuticals, LLC

Alopexx Pharmaceuticals was founded to develop a promising new treatment for serious Staphylococcus aureus infections, including those caused by methicillin-resistant strains known as MRSA. In the past decade MRSA has emerged as a major public health problem. Due to the increasing volume of antimicrobial usage around the world, MRSA and many bacteria have become increasingly resistant to most commonly used antibiotics. mAb F598 is a fully human monoclonal antibody that has the potential to serve as an alternative to antibiotics in the fight against MRSA and other S. aureus infections. Unlike antibiotics, monoclonal antibodies will not lead to the development of bacterial resistance. The target of the antibody is a carbohydrate on the bacterial capsule known as PNAG. PNAG has been found to be a critical factor in the virulence and immune response to MRSA as well as non-MRSA staphylococcal infections and is also expressed by other bacterial pathogens. Alopexx Pharmaceuticals, LLC was co-founded by Gerald Pier, PhD and Daniel Vlock, MD. Its aim is to develop and explore the use of novel therapies for the treatment and prevention of MRSA and other serious infections. For more information contact Daniel Vloc
'/>"/>

SOURCE Laureate Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Thomson Scientific Salutes Nobel Laureate Prize Winners, Many of Whom Were Selected as Thomson Scientific Laureates in 2006
2. American Scientists Named as Laureates of the 2008 (24th) Japan Prize
3. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
4. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
5. Laureate Pharma Appoints Gary Swan as Vice President of Operations
6. Laureate Pharma Reports Record Growth for 2007
7. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
8. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
11. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... OAKS, Calif., July 10, 2014   Ceres, Inc ... and seed company, announced today financial results for the ... update on its business. Ceres reported that ... in product performance this growing season in Brazil, which ... affected the company,s sorghum evaluation areas for part of ...
(Date:7/10/2014)... new study published today in the journal PNAS ... found that time of day and sleep deprivation have ... be crucial when looking at the best time of ... heart disease, and for administering medicines effectively. , Researchers ... Cancer Research, London, investigated the links between sleep deprivation, ...
(Date:7/10/2014)... sit upside down forever. Nanophysics makes sure of that. Mechanics ... just published in Physical Review E . Knowledge that ... that seem to be able to sit still forever, and ... years. We will soon be able to buy smart new ... But the fact is, sooner or later the grip is ...
(Date:1/15/2014)... , Using an approach akin to assembling a ... Standards and Technology (NIST) researchers have succeeded in ... reduces the flammability of foam commonly used in ... flammability of the nanotube-coated polyurethane foam was reduced ...
Breaking Biology Technology:Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9Time of day crucial to accurately test for diseases, new research finds 2Even geckos can lose their grip 2Layered security: Carbon nanotubes promise improved flame-resistant coating 2
... DIEGO, CA, July 7, 2008 Senomyx, Inc.,(Nasdaq: ... using proprietary technologies,to discover and develop novel flavor ... announced today a one-year extension of its,exclusive collaborative ... a unit of Cadbury plc, for the discovery ...
... Bernard Barataud, EVRY, France, July 7 The ... head the laboratory created in 1990 by the AFM,(French ... has decided to hand over the reins after heading ... and 2008., Yves Champey is a physician by ...
... The Eniva Research Group has,released results ... Pauling,Micronutrient Research Institute at Oregon State University ... DNA protective,anti-mutagenic activity for human cells. This ... an ongoing investigative effort to further identify,mechanisms ...
Cached Biology Technology:SENOMYX ANNOUNCES EXTENSION OF DISCOVERY AND DEVELOPMENT COLLABORATION WITH CADBURY PLC 2SENOMYX ANNOUNCES EXTENSION OF DISCOVERY AND DEVELOPMENT COLLABORATION WITH CADBURY PLC 3A New President at the Head of the Genethon Laboratory 2Eniva VIBE(R) Nutraceutical Tested at Linus Pauling Micronutrient Research Institute and Found to Possess DNA Protective Properties 2
(Date:7/10/2014)... housed at NJIT,s business incubator, received a $1.4 million ... will use to staunch bleeding during brain surgery. , ... and the natural bio-polymer solutions in the gel will ... seconds. , The gel can shorten an intracranial ... less time for the patient,s skull to be open ...
(Date:7/10/2014)... a family of enzymes known as heme enzymes, due ... active site. At the centre of the heme cofactor ... when a reacting heme is in an intermediate state ... for decades is whether this oxidation involves just an ... this fundamental question has implications for understanding oxidative processes ...
(Date:7/10/2014)... The American Chemical Society (ACS) announced today that ... journal ACS Infectious Diseases as editor-in-chief. ... January 2015, the pioneering journal will meet a ... chemistry-focused infectious diseases research. , "Our vision is ... a strong emphasis on the basic science that ...
Breaking Biology News(10 mins):A start-up at NJIT develops bleeding-control gel for brain surgery 2Neutron crystallography solves long-standing biological mystery 2Neutron crystallography solves long-standing biological mystery 3ACS Infectious Diseases: Unique chemistry journal names editor 2
... discovered on an unexplored mountain range in northern ... Conservation Programme. It was named "Yariguies Brush-Finch," with ... The new brush-finch was described by an Anglo-Colombian ... and Blanca Huertas (Natural History Museum and University ...
... New research identifies an important gene that influences several ... study, funded by National Institutes of Drug Abuse, was ... Meeting. , Investigator Marina Picciotto, PhD, associate professor ... that nicotine can increase activity of a molecule called ...
... the Chlamydia bacterium, which causes a sexually transmitted disease ... evolutionary heritage, which is not found in most other ... an effective cure for Chlamydia infections. , "The unique ... proposed by others," said Thomas Leustek," a professor in ...
Cached Biology News:New bird discovered on unexplored Columbian mountain 2New research identifies gene important for nicotine's effects on the brain 2Common ancestry of bacterium and plants could be key to an effective new treatment for chlamydia 2Common ancestry of bacterium and plants could be key to an effective new treatment for chlamydia 3
... Characteristics:, Antibody Binding: High, 400 ng ... volume) , Binding Interaction: Hydrophobic/Ionic , Performance ... (bottom): Flat , Maximum Well Volume: 360 ... tray ,Features, Special optically clear ...
...
...
... enables early selection of the best ... quantitative data for sensitivity, dynamic range, ... Furthermore quantitative antibody fingerprints can be ... your antibodies., The full-service package includes ...
Biology Products: